307 related articles for article (PubMed ID: 36551961)
1. Beyond Imaging and Genetic Signature in Glioblastoma: Radiogenomic Holistic Approach in Neuro-Oncology.
Gatto L; Franceschi E; Tosoni A; Di Nunno V; Tonon C; Lodi R; Agati R; Bartolini S; Brandes AA
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551961
[TBL] [Abstract][Full Text] [Related]
2. Radiogenomic Predictors of Recurrence in Glioblastoma-A Systematic Review.
Corr F; Grimm D; Saß B; Pojskić M; Bartsch JW; Carl B; Nimsky C; Bopp MHA
J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330402
[TBL] [Abstract][Full Text] [Related]
3. Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma.
Xi YB; Guo F; Xu ZL; Li C; Wei W; Tian P; Liu TT; Liu L; Chen G; Ye J; Cheng G; Cui LB; Zhang HJ; Qin W; Yin H
J Magn Reson Imaging; 2018 May; 47(5):1380-1387. PubMed ID: 28926163
[TBL] [Abstract][Full Text] [Related]
4. State of Radiomics in Glioblastoma.
Taha B; Boley D; Sun J; Chen CC
Neurosurgery; 2021 Jul; 89(2):177-184. PubMed ID: 33913492
[TBL] [Abstract][Full Text] [Related]
5. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB
BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012
[TBL] [Abstract][Full Text] [Related]
6. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
7. Ventricle contact is associated with lower survival and increased peritumoral perfusion in glioblastoma.
van Dijken BRJ; Jan van Laar P; Li C; Yan JL; Boonzaier NR; Price SJ; ; van der Hoorn A
J Neurosurg; 2018 Oct; 131(3):717-723. PubMed ID: 30485234
[TBL] [Abstract][Full Text] [Related]
8. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
[TBL] [Abstract][Full Text] [Related]
9. Introduction to radiomics and radiogenomics in neuro-oncology: implications and challenges.
Beig N; Bera K; Tiwari P
Neurooncol Adv; 2020 Dec; 2(Suppl 4):iv3-iv14. PubMed ID: 33521636
[TBL] [Abstract][Full Text] [Related]
10. Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging.
Ahn SS; Shin NY; Chang JH; Kim SH; Kim EH; Kim DW; Lee SK
J Neurosurg; 2014 Aug; 121(2):367-73. PubMed ID: 24949678
[TBL] [Abstract][Full Text] [Related]
11. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.
Wei J; Yang G; Hao X; Gu D; Tan Y; Wang X; Dong D; Zhang S; Wang L; Zhang H; Tian J
Eur Radiol; 2019 Feb; 29(2):877-888. PubMed ID: 30039219
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and Predictive Value of Integrated Qualitative and Quantitative Magnetic Resonance Imaging Analysis in Glioblastoma.
Verduin M; Primakov S; Compter I; Woodruff HC; van Kuijk SMJ; Ramaekers BLT; te Dorsthorst M; Revenich EGM; ter Laan M; Pegge SAH; Meijer FJA; Beckervordersandforth J; Speel EJ; Kusters B; de Leng WWJ; Anten MM; Broen MPG; Ackermans L; Schijns OEMG; Teernstra O; Hovinga K; Vooijs MA; Tjan-Heijnen VCG; Eekers DBP; Postma AA; Lambin P; Hoeben A
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33578746
[TBL] [Abstract][Full Text] [Related]
13. Improving MGMT methylation status prediction of glioblastoma through optimizing radiomics features using genetic algorithm-based machine learning approach.
Do DT; Yang MR; Lam LHT; Le NQK; Wu YW
Sci Rep; 2022 Aug; 12(1):13412. PubMed ID: 35927323
[TBL] [Abstract][Full Text] [Related]
14. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification.
Wenger A; Ferreyra Vega S; Kling T; Bontell TO; Jakola AS; Carén H
Neuro Oncol; 2019 May; 21(5):616-627. PubMed ID: 30668814
[TBL] [Abstract][Full Text] [Related]
15. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator.
Kolakshyapati M; Adhikari RB; Karlowee V; Takayasu T; Nosaka R; Amatya VJ; Takeshima Y; Akiyama Y; Sugiyama K; Kurisu K; Yamasaki F
J Neurosurg; 2018 Mar; 128(3):667-678. PubMed ID: 28362236
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive O
Hajianfar G; Shiri I; Maleki H; Oveisi N; Haghparast A; Abdollahi H; Oveisi M
World Neurosurg; 2019 Dec; 132():e140-e161. PubMed ID: 31505292
[TBL] [Abstract][Full Text] [Related]
17. Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status.
Romano A; Calabria LF; Tavanti F; Minniti G; Rossi-Espagnet MC; Coppola V; Pugliese S; Guida D; Francione G; Colonnese C; Fantozzi LM; Bozzao A
Eur Radiol; 2013 Feb; 23(2):513-20. PubMed ID: 22875158
[TBL] [Abstract][Full Text] [Related]
18. Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma.
Kickingereder P; Neuberger U; Bonekamp D; Piechotta PL; Götz M; Wick A; Sill M; Kratz A; Shinohara RT; Jones DTW; Radbruch A; Muschelli J; Unterberg A; Debus J; Schlemmer HP; Herold-Mende C; Pfister S; von Deimling A; Wick W; Capper D; Maier-Hein KH; Bendszus M
Neuro Oncol; 2018 May; 20(6):848-857. PubMed ID: 29036412
[TBL] [Abstract][Full Text] [Related]
19. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
